Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Multicenter, Open-label, Dose Regimen Determination and Dose Expansion Trial to Evaluate the Safety, Tolerability, Anti-tumor Activity, and an Optimal Dose Regimen of Patritumab Deruxtecan (HER3-DXd) With Trastuzumab Deruxtecan (T-DXd) in Participants With Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer (HERTHENA-Breast02)

NCT07701941 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT07701941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07701941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Multicenter, Open-label, Dose Regimen Determination and Dose Expansion Trial to Evaluate the Safety, Tolerability, Anti-tumor Activity, and an Optimal Dose Regimen of Patritumab Deruxtecan (HER3-DXd) With Trastuzumab Deruxtecan (T-DXd) in Participants With Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer (HERTHENA-Breast02)
Lead sponsor
Daiichi Sankyo
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 17, 2026
Completion date
May 1, 2032
Enrollment
220 (estimated)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

her2-low or her2-ultralow, hormone receptor positive, unresectable or metastatic breast cancer